Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01E PROTEIN KINASE INHIBITORS
L01EH Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors
L01EH02 Neratinib
D10898 Neratinib maleate <US>
USP drug classification [BR:br08302]
Antineoplastics
Molecular Target Inhibitors
Neratinib
D10898 Neratinib maleate
Drug groups [BR:br08330]
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG01917 Receptor tyrosine kinase inhibitor
DG03158 HER2 inhibitor
DG02303 Neratinib
D10898 Neratinib maleate
Drug classes [BR:br08332]
Antineoplastic
DG03158 HER2 inhibitor
D10898 Neratinib maleate
Target-based classification of drugs [BR:br08310]
Protein kinases
Receptor tyrosine kinases (RTK)
EGFR family
EGFR
D10898 Neratinib maleate <US>
ERBB2* (HER2, CD340) [HSA_VAR:2064v12064v3]
D10898 Neratinib maleate <US>
ERBB4 (HER4)
D10898 Neratinib maleate <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D10898
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D10898
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D10898
Pharmacogenomic biomarkers [br08341.html]
Somatic variations in targeted cancer therapies
D10898
Drug groups [BR:br08330]
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG01917 Receptor tyrosine kinase inhibitor
DG03158 HER2 inhibitor
DG02303 Neratinib